Taivex announced that T-1101 has received approval from the U.S. Food and Drug Administration (FDA) to advance to Phase II clinical trials. This trial will
Taivex announced that its Phase I clinical trial drugs, T-1101 and T-1201, have been invited to present their project progress at the Korean Society of
Taivex is dedicated to the development of novel cancer therapeutics and possesses multiple First-in-Class/Best-in-Class anticancer targeted drugs. Taivex will attend the Bio Asia-Taiwan 2024, BIO
The groundbreaking discovery and development of T-1201, a novel targeting small molecule-drug conjugate (SN38), and T-1301, an innovative multi-targeted tyrosine kinase inhibitor (TKI), have been
Taivex has announced that all three Phase I clinical projects, T-1101, T-1201, and T-1301, have been selected to present their project progress at the American
Taivex Therapeutics attended the 2024 BIO-Europe SPRING conference in Barcelona, Spain (https://informaconnect.com/bioeurope-spring/) from March 18th to 20th. During the conference, Taivex engaged in discussions with
T-1301 Phase I clinical trial was initiated in Mid-December, 2021 in multiple centers in Taiwan. Getting through the tough 2022Q2 due to COVID-19 affected patient
The discovery and development of our first-in-class Hec1/Nek2 inhibitor, oral anti-cancer drug T-1101 (Tosylate), have been accepted for an oral presentation at the 19th Annual
T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021 in multiple centers in Taiwan. T-1301 is a small molecular multi-target tyrosine kinase
Following IND approval by the US FDA in Mid-June, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on June
